Next Article in Journal
Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy
Next Article in Special Issue
The Cycling of Intracellular Calcium Released in Response to Fluid Shear Stress Is Critical for Migration-Associated Actin Reorganization in Eosinophils
Previous Article in Journal
Myeloid Cells in Glioblastoma Microenvironment
Open AccessReview

Discovery, Function, and Therapeutic Targeting of Siglec-8

1
Allakos Inc., Redwood City, CA 94065, USA
2
Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
*
Author to whom correspondence should be addressed.
Cells 2021, 10(1), 19; https://doi.org/10.3390/cells10010019
Received: 30 November 2020 / Revised: 18 December 2020 / Accepted: 20 December 2020 / Published: 24 December 2020
(This article belongs to the Special Issue Eosinophils beyond IL-5)
Siglecs (sialic acid-binding immunoglobulin-like lectins) are single-pass cell surface receptors that have inhibitory activities on immune cells. Among these, Siglec-8 is a CD33-related family member selectively expressed on human mast cells and eosinophils, and at low levels on basophils. These cells can participate in inflammatory responses by releasing mediators that attract or activate other cells, contributing to the pathogenesis of allergic and non-allergic diseases. Since its discovery in 2000, initial in vitro studies have found that the engagement of Siglec-8 with a monoclonal antibody or with selective polyvalent sialoglycan ligands induced the cell death of eosinophils and inhibited mast cell degranulation. Anti-Siglec-8 antibody administration in vivo to humanized and transgenic mice selectively expressing Siglec-8 on mouse eosinophils and mast cells confirmed the in vitro findings, and identified additional anti-inflammatory effects. AK002 (lirentelimab) is a humanized non-fucosylated IgG1 antibody against Siglec-8 in clinical development for mast cell- and eosinophil-mediated diseases. AK002 administration has safely demonstrated the inhibition of mast cell activity and the depletion of eosinophils in several phase 1 and phase 2 trials. This article reviews the discovery and functions of Siglec-8, and strategies for its therapeutic targeting for the treatment of eosinophil- and mast cell-associated diseases. View Full-Text
Keywords: Siglec-8; mast cells; eosinophils; monoclonal antibodies; glycan ligands; AK002; lirentelimab Siglec-8; mast cells; eosinophils; monoclonal antibodies; glycan ligands; AK002; lirentelimab
Show Figures

Figure 1

MDPI and ACS Style

Youngblood, B.A.; Leung, J.; Falahati, R.; Williams, J.; Schanin, J.; Brock, E.C.; Singh, B.; Chang, A.T.; O’Sullivan, J.A.; Schleimer, R.P.; Tomasevic, N.; Bebbington, C.R.; Bochner, B.S. Discovery, Function, and Therapeutic Targeting of Siglec-8. Cells 2021, 10, 19. https://doi.org/10.3390/cells10010019

AMA Style

Youngblood BA, Leung J, Falahati R, Williams J, Schanin J, Brock EC, Singh B, Chang AT, O’Sullivan JA, Schleimer RP, Tomasevic N, Bebbington CR, Bochner BS. Discovery, Function, and Therapeutic Targeting of Siglec-8. Cells. 2021; 10(1):19. https://doi.org/10.3390/cells10010019

Chicago/Turabian Style

Youngblood, Bradford A.; Leung, John; Falahati, Rustom; Williams, Jason; Schanin, Julia; Brock, Emily C.; Singh, Bhupinder; Chang, Alan T.; O’Sullivan, Jeremy A.; Schleimer, Robert P.; Tomasevic, Nenad; Bebbington, Christopher R.; Bochner, Bruce S. 2021. "Discovery, Function, and Therapeutic Targeting of Siglec-8" Cells 10, no. 1: 19. https://doi.org/10.3390/cells10010019

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop